Cerus Corp
NASDAQ:CERS

Watchlist Manager
Cerus Corp Logo
Cerus Corp
NASDAQ:CERS
Watchlist
Price: 1.79 USD 7.19% Market Closed
Market Cap: 332.4m USD
Have any thoughts about
Cerus Corp?
Write Note

Operating Margin
Cerus Corp

-6%
Current
-19%
Average
4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-6%
=
Operating Profit
-11.8m
/
Revenue
197.9m

Operating Margin Across Competitors

Country US
Market Cap 332.3m USD
Operating Margin
-6%
Country JP
Market Cap 6.8T JPY
Operating Margin
28%
Country CH
Market Cap 37.9B CHF
Operating Margin
13%
Country DK
Market Cap 200.9B DKK
Operating Margin
27%
Country US
Market Cap 16.9B USD
Operating Margin
17%
Country KR
Market Cap 9.9T KRW
Operating Margin
-245%
Country CA
Market Cap 6.9B USD
Operating Margin
4%
Country CN
Market Cap 48.6B CNY
Operating Margin
46%
Country US
Market Cap 6.3B USD
Operating Margin
32%
Country US
Market Cap 6.1B USD
Operating Margin
12%
Country UK
Market Cap 4.8B GBP
Operating Margin
13%
No Stocks Found

Cerus Corp
Glance View

Market Cap
332.3m USD
Industry
Health Care

Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 294 full-time employees. The company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.

CERS Intrinsic Value
1.55 USD
Overvaluation 13%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-6%
=
Operating Profit
-11.8m
/
Revenue
197.9m
What is the Operating Margin of Cerus Corp?

Based on Cerus Corp's most recent financial statements, the company has Operating Margin of -6%.